Search

BR-112021019351-B1 - Bidens Pilosa and its phytochemicals for use in the prevention and treatment of diarrhea.

BR112021019351B1BR 112021019351 B1BR112021019351 B1BR 112021019351B1BR-112021019351-B1

Abstract

BIDENS PILOSA AND ITS PHYTOCHEMICALS FOR USE IN THE PREVENTION AND TREATMENT OF DIARRHEA. A composition comprising Bidens pilosa or an active compound isolated from Bidens pilosa for use in the treatment, inhibition, and/or reduction of the presence of pathogenic intestinal microbiota in an animal in need thereof is disclosed. The pathogenic intestinal microbiota is at least one selected from the group consisting of Brachyspira, porcine epidemic diarrhea virus (PEDV), transmissible gastroenteritis coronavirus (TGEV), and Rotavirus (RV). The composition is also for use in the treatment, inhibition, and/or reduction of the occurrence of swine diarrhea, swine dysentery, swine viral infection, and to increase the percentage of swine carcass and bone weight. In one embodiment, the composition is for use in the treatment, inhibition, and/or reduction of the occurrence of Brachyspira-associated swine dysentery.

Inventors

  • Wen-Chin Yang
  • Yu-Chuan Liang

Assignees

  • ACADEMIA SINICA

Dates

Publication Date
20260310
Application Date
20200322
Priority Date
20190328

Claims (15)

  1. 1. Use of a composition, CHARACTERIZED by the fact that it consists of Bidens pilosa extract in the manufacture of a medicament to treat, inhibit and/or reduce the presence of pathogenic intestinal microbiota in a pig in need thereof, wherein the pathogenic intestinal microbiota is at least one selected from the group consisting of Brachyspira, porcine epidemic diarrhea virus (PEDV), transmissible gastroenteritis coronavirus (TGEV) and Rotavirus (RV).
  2. 2. Use of a composition, CHARACTERIZED by the fact that it consists of Bidens pilosa extract and an animal feed in the manufacture of a medicament to treat, inhibit and/or reduce the occurrence of swine diarrhea, swine dysentery, swine viral infection and increase the percentage of swine carcass and bone weight in a pig in need thereof.
  3. 3. Use, according to claim 2, CHARACTERIZED in that swine diarrhea, swine dysentery and swine viral infection are associated with at least one pathogenic intestinal microbiota selected from the group consisting of Brachyspira, porcine epidemic diarrhea virus (PEDV), transmissible gastroenteritis coronavirus (TGEV) and Rotavirus (RV).
  4. 4. Use of a composition, CHARACTERIZED by the fact that it consists of Bidens pilosa extract and an animal feed in the manufacture of a medicament to treat, inhibit and/or reduce the occurrence of swine dysentery associated with Brachyspira and increase the percentage of swine carcass and bone weight in a pig in need thereof.
  5. 5. Use, according to any one of claims 1 to 4, CHARACTERIZED in that the pig in need thereof is a weaned pig.
  6. 6. Use, according to any one of claims 1 to 4, CHARACTERIZED in that the animal in need thereof is an adult pig.
  7. 7. Use, according to any one of claims 1 to 4, CHARACTERIZED in that the Bidens pilosa extract comprises an active polyacetylene compound of formula (I): where R1 is H or CH3; R2 is a monosaccharide; R3 is H or COCH2COOH; m = 3 or 4; n = 0 or i; o = i or 2; and p = i or 2.
  8. 8. Use according to claim 7, CHARACTERIZED in that the active polyacetylene compound is at least one selected from the group consisting of
  9. 9. Use, according to any of claims 1 to 4, CHARACTERIZED by the fact that the Bidens pilosa extract is in powder form.
  10. 10. Use, according to any one of claims 1 to 4, CHARACTERIZED in that the composition is in the form of food, an animal feed material or a medicament.
  11. 11. Use, according to any one of claims 1 to 4, CHARACTERIZED in that the composition is in a dosage form selected from the group consisting of oral, capsule, suppository and parenteral.
  12. 12. Use, according to any of claims 1 to 4, CHARACTERIZED by the fact that the Bidens pilosa extract is at a dosage of not less than 1 μg/kg of body weight of the pig in need thereof.
  13. 13. Use, according to any of claims 2 or 4, CHARACTERIZED in that the Bidens pilosa extract varies from 0.0005% to 15% (w/w).
  14. 14. Use, according to any one of claims 2 or 4, CHARACTERIZED in that the Bidens pilosa extract varies from 0.05% to 15% (w/w).
  15. 15. Use, according to any one of claims 1 to 4, CHARACTERIZED in that the Bidens pilosa extract comprises cytopiloin.

Description

FIELD OF THE INVENTION [001] The present invention generally relates to Bidens pilosa for use in the prevention, relief and treatment of diarrhea and, more specifically, to Bidens pilosa and its phytochemicals for use in the prevention, relief and treatment of swine diarrhea. FUNDAMENTALS OF THE INVENTION [002] Diarrhea and dysentery are the most important problems in the swine industry. It can occur from weaning until the last day of finishing. It can become a chronic condition that continues for weeks. Antimicrobial growth promoters (AGPs) as feed additives have proven effective in reducing swine diarrhea and increasing growth performance in the swine industry. However, AGPs are known to induce antibiotic resistance in pathogens. For this reason, AGPs for animals have been banned in the European Union since 2006. [003] Plants have been an extraordinary source of medicines for humans and animals since antiquity. A herbal approach can reduce or replace the abuse or misuse of AGP in swine and aid in meat production. SUMMARY OF THE INVENTION [004] In one aspect, the invention relates to the use of a composition comprising Bidens pilosa or an active compound isolated from Bidens pilosa in the manufacture of a medicament for treating, inhibiting and/or reducing the presence of pathogenic intestinal microbiota in an animal in need thereof, wherein the pathogenic intestinal microbiota is at least one selected from the group consisting of Brachyspira spp., porcine epidemic diarrhea virus (PEDV), transmissible gastroenteritis coronavirus (TGEV) and Rotavirus (RV). [005] The composition of the invention is also for use in increasing the percentage of pork carcass and bone weight. [006] In another aspect, the invention relates to the use of a composition comprising Bidens pilosa or an active compound isolated from Bidens pilosa in the manufacture of a medicament to treat, inhibit and/or reduce the occurrence of swine diarrhea, swine dysentery, swine viral infection and increase the percentage of swine carcass and bone weight. [007] In addition, in another aspect, the invention relates to the use of a composition comprising Bidens pilosa or an active compound isolated from Bidens pilosa in the manufacture of a medicament to treat and/or reduce the occurrence of Brachyspira-associated swine dysentery and increase the percentage of swine carcass and bone weight. [008] In one embodiment of the invention, swine diarrhea, swine dysentery, and swine viral infection are associated with at least one pathogenic intestinal microbiota selected from the group consisting of Brachyspira spp., porcine epidemic diarrhea virus (PEDV), transmissible gastroenteritis coronavirus (TGEV), and rotavirus (RV). [009] In one embodiment, the pathogenic gut microbiota may be selected from Brachyspira spp. The pathogenic gut microbiota may be Brachyspira hyodysenteriae. The animal in need may be a weaned pig or an adult pig. [010] In another embodiment, the active compound isolated from Bidens pilosa is a polyacetylene compound of formula (I): where R1 is H or CH3; R2 is a monosaccharide; R3 is H or COCH2COOH; m = 3 or 4; n = 0 or 1; o = 1 or 2; and p = 1 or 2. [011] In another embodiment, the active compound isolated from Bidenspilosa is at least one selected from the group consisting of [012] Bidens pilosa may be in powder form. The composition may be in the form of food, an animal feed material or a medicine. [013] In another embodiment, the composition is in a dosage form selected from the group consisting of oral, capsule, suppository and parenteral. [014] In another embodiment, Bidens pilosa or the active compound isolated from Bidens pilosa is at a dosage of not less than 1 μg/kg of body weight of the animal in need thereof. [015] In another embodiment, the composition comprises an animal feed and Bidens pilosa ranging from 0.0005% to 15% (w/w). [016] In another embodiment, the composition comprises an animal feed and Bidens pilosa ranging from 0.05% to 15% (w/w). The composition may comprise an animal feed and Bidens pilosa ranging from 0.1% to 15% (w/w), 1% to 15% (w/w) or 1% to 10% (w/w). [017] In another embodiment, the active compound isolated from Bidens pilosa is cytopiloin. [018] These and other aspects will become evident from the following description of the preferred modalities taken together with the following designs, although variations and modifications to them may be made without departing from the spirit and scope of the innovative concepts of the disclosure. [019] The accompanying drawings illustrate one or more embodiments of the invention and, together with the written description, serve to explain the principles of the invention. Whenever possible, the same reference numbers are used throughout the drawings to refer to the same or similar elements of an embodiment. BRIEF DESCRIPTION OF THE DRAWINGS [020] FIG. 1 shows a dosage scheme. Five groups of weaned pigs treated for 4 weeks were fed antibiotic growth promoter (A